Jeff Healey
Results from the first randomized trial to test subcutaneous (S-ICD) versus transvenous (TV-ICD) implantable cardioverter defibrillators will be presented at Heart Rhythm 2022 on Saturday Apr 30, 2:15 to 3:15 PM Pacific Daylight Time. (session LB-733).
PHRI Senior Scientist Jeff Healey will present the findings of the trial, Avoid Transvenous Leads in Appropriate Subjects (ATLAS) S-ICD. The trial followed patients for six months after their device was implanted, to see if the use of a S-ICD (implanted under the skin, without leads placed in heart such as with the TV-ICD) reduced the rate of perioperative complications.
The lead is the least reliable component of the TV-ICD system and may contribute to premature revision of the system in 2-20% of patients during the typical lifespan of an ICD generator,” Healey has cited in the rationale for ATLAS S-ICD. “Many of these revisions and associated complications could be avoided in a lead that was not placed in the vasculature or heart.”
Healey also noted that younger patients are under-represented in ICD trials. ATLAS S-ICD patients are in the 18- to 60-year-old range.
Healey’s talk will be part of the session, Late Breaking Clinical Trials (LBCT) – Randomized Clinical Trials – at Heart Rhythm 2022. All LBCT presentations will happen live in San Francisco, California.
Banner on this page: Jeff Healey is seen implanting a subcutaneous defibrillator in a patient at the electrophysiology lab at Hamilton Health Sciences (HHS). Photo credit: Owen Thomas, HHS.
